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A B ST R AC T  
 
Fetal rhabdomyomatous nephroblastoma is a weird variant of Wilms tumor. It’s a chemo-resistant 
tumor, characterized for invading the collecting system, and having greater rates of bilateral 
involvement. The tumor chiefly consists of fetal striated muscle with particularly distinct striations 
and central nuclei, and isolated regions of typical trimorphic nephroblastoma. The following article 
brings in a new case of this rare pathology, associated with a review of the literature 
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Introduction 
Fetal rhabdomyomatous nephroblastoma 
(FRN) is a weird variant of Wilms tumor 
(WT), first described by Eberth in 1872 as 
“myoma sarcomatodes renum”. The tumour 
chiefly consists of fetal striated muscle with 
particularly distinct striations and central 
nuclei, and isolated regions of typical 
trimorphic nephroblastoma. It is a chemo-
resistant tumor, characterized by invading the 
collecting system, and having greater rates of 
bilateral involvement [1-9]. The following 
article brings the principal clinic, therapeutic 
and evolutive characteristics in a new case of 




23-month-old girl with a palpable abdominal 
mass of a month of evolution. On physical 
examination, the patient was in good general 
conditions, adequate weight and height for age. 
A large firm mass was palpated in the right 
flank, associated with collateral circulation and 
hepatomegaly, extending to the left 
hypochondrium.  
Abdominal ultrasonography showed a solid 
mass of 125x128x110 mm replacing the right 
kidney. Contrast enhanced thoraco-abdominal 
computed tomography (CT) showed a right 
kidney lesion of 135x130x128 mm, suggestive 
of WT, with anterior displacement of the right 
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lobule of the liver and retroperitoneal 
structures; collapsed inferior vena cava and 
unspecific subpleural nodules in superior 
lobules [Fig. 1].  
 
 
Fig. 1.  Contrast enhanced CT, showing a right 
renal mass of 135x130x128 mm, suggestive of 
Wilms tumor. 
 
Elevated blood pressure was found, with 
diagnosis of state 2 hypertension, without vital 
organs compromised. Amlodipine, clonidine 
and captopril were indicated. 
An abdominal mass suggestive of WT as a first 
option was considered, but a neuroblastoma 
was also considered because of the early 
appearance. Taking into account the possible 
metastatic disease in the lung, the size of the 
lesion, the involvement of near structures, and 
the high risk of intraoperative tumoral rupture, 
neoadjuvant chemotherapy was initiated, with 
the following protocol: 
 
Week 0: Actinomycin 45ug/kg, 
Week 1: Vincrystin 0.05mg/kg, 
Week 2: Vincrystin 0.05mg/kg, 
Week 3: Vincrystin 0.05mg/kg,  
plus Doxorrubycin 1.5 mg/kg,  
Week 4: Vincrystin 0.05mg/kg, 
Week 5: Vincrystin 0.05mg/kg. 
 
She presented fever during the third week of 
treatment, associated with abdominal pain, 
without observing decrease in the size of the 
mass in physical examination or improvement 
of blood pressure rates. 24 hours’ urine 
catecholamine’s were taken to rule out 
neuroblastoma (vanillymandelic and 
homovanillic acid), with normal results. 
Control magnetic nuclear resonance showed a 
kidney dependent abdominal mass occupying 
the right hemi abdomen, of greater size 
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Fig. 2A-C. Magnetic nuclear resonance, 
showing increase of the tumoral mass, with 
bleeding and necrosis areas (A) Axial T1.  (B) 
Sagittal (C) Axial T2. 
 
The chemotherapy protocol continued for 5 
more weeks. A right radical nephrectomy was 
performed, finding an approximately 20 cm 
tumor, adhered to the vena cava and right 
kidney artery, with solid consistence and cystic 
areas, plus enlarged interaortocaval lymphatic 
nodes up to 1.5 cm. Due to 650 cc of bleeding, 
she required transfusion of 400 cc of packed 
red cells and 160 cc of plasma. 
Post-operative evolution was satisfactory, 
without complications, and improvement of 
blood pressure values. Adjuvant chemotherapy 
continued (week 6), meanwhile the pathology 
report was ready. 
The final pathology report showed an irregular, 
light brown mass that weighted 1.249 grams, 
and measured 17x13x11 cm, with solid and 
necrotic areas. A renal remnant of 3x3x2 cm 
was found. It was classified as a FRN, with the 
following histologic findings; Tumor mass, 
predominantly stromal, with occasional 
mitosis, trapped renal tubules, skeletal muscle 
heterologous differentiation and fusocellular 
mesenchymal differentiation. 
Immunohistochemistry showed positivity in 
tumoral cells with Vimentine and CD34 in the 
stromal component; myogenin in the 
heterologous differentiation component, and 
WTi in the tubular epithelial component, as 
EMA (epithelial membrane antigen). The 





Fig. 3. Histology and immunohistochemistry. 
(A) Striated muscle heterologous 
differentiation. (B) Positive WTi in the 
epithelial tubular component. (C) Positive 
CD34 in the stromal component. 
 
PET scan was done 2 months after surgery, 
without finding lesions that suggested the 
presence of tumoral disease. Expectant 
management was decided. 
 
Discussion 
FRN is a monophasic mesenchymal variant of 
WT [1], with an estimated prevalence of 1.5-
4.5%. It’s bilateral in 30% of cases. Local 
relapses and the presence of metastatic disease 
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imply a worse prognosis. This tumor doesn’t 
respond well to chemotherapy protocols 
(because of its mesenchymal component: fetal 
rhabdomyomatous tissue) [2].  Wigger [1] first 
used the term fetal rabdomyomatous 
nephroblastoma in 1976.   
It is microscopically characterized by striated 
muscle with different striations and central 
nuclei. The histology of this muscle reminds 
that to fetal striated muscle, and it’s 
accompanied by undifferentiated tissue areas, 
neoplastic epithelium and mesenchymal 
components, such as adipose and myxoid 
tissue, and cartilage islands. 
It is microscopically and macroscopically 
similar to congenital mesoblastic nephroma, 
and the only difference is quantitative, because 
in this one there is a predomination of smooth 
muscle, while in FRN the presence of striated 
muscle fibers predominates [3]. Nonetheless, 
congenital mesoblastic nephroma has unique 
characteristics, as it is considered the most 
common solid tumor of the newborn, usually 
identified in the first 3 months of life. 
It’s origin is given by proliferation of early 
nephrogenic mesenchymal tissue with 
monomorphic histology, mesenchymal cells 
proliferations, and embrionary metaplasm 
soaked in normal renal tissue. It’s usually 
benign, with complete healing after a 
nephrectomy with wide margins [4]. 
It’s known that FRN is usually of greater size 
than WT, but its behavior in a complete 
resection scenario is less aggressive. There is 
an important difference in the age of 
presentation, according to Wigger, FRN 
predominates in 1-year-old [1], and WT 
presents in patients of 2-3 years old. There 
aren’t reported cases in patients older than 4 
years old.   
Beckwit et al. [5] described that the clinical 
behavior of nephroblastoma is defined by the 
aggressiveness of the tumor. A blastomatous 
predominant WT is associated with a high 
aggressiveness pattern (76% of cases in 3-4 
stage), but due to its good answer to 
chemotherapy, free disease survival rates are 
high. FRN is usually diagnosed in early stages 
(80%), but it is chemo resistant, so patients 
present low survival rates if the tumor is not 
totally resected. 
Pollono [6] described a 14 patient’s cohort 
diagnosed with FRN, with a mean age of 27 
months, and a bilateral presentation of 22%. 
After cytoreduction and adjuvant therapy, only 
6 patients were free of disease, and 8 had died. 
The same findings were reported by Saba [7], 
and Maes et al [8], whom noted poor survival 
rates in patients with FRN taken into 
incomplete resection of the tumor. 
Anderson proposed the hypothesis that a poor 
response to chemotherapy in patients with 
bilateral WT was associated with post 
chemotherapy presence of rhabdomyomatous 
histology [9]. He demonstrated a significant 
association between post chemotherapy 
rhabdomyomatous differentiation and poor 
radiologic answer. 
Tumor size has been employed as a prognosis 
indicator, due to the fact that in classic 
nephroblastoma, it is inversely related with 
survival rates [10,11]. Some authors have 
described that volumes greater than 551 cc, 
survival rates are close to zero. Maes found a 
mean volume of 965 cc (17.3 to 2520 cc) in 
patients with FRN [8]. However, the mean 
survival rate in these patients was of 4 years.   
There is no way to differentiate FRN from 
classic WT in initial studies. Nonetheless, it is 
important to emphasize that initial study of an 
abdominal mass is done with ultrasonography. 
When solid lesions suggestive of malignant 
disease are found, a contrast-enhanced CT 
must be done, because of its greater sensibility 
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for establishing vascular, local and lymphatic 
extension [12]. Magnetic resonance is the 
imaging study of choice to determine vascular 
involvement [12]. 
Conclusions 
FRN is a variant of WT, with better prognosis 
when local control is adequate. Diagnosis is 
histological. It responds poorly to 
chemotherapy, so an aggressive resection is 
important to achieve greater survival rates.  
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